Information Provided By: 
Fly News Breaks for March 9, 2016
OSIR
Mar 9, 2016 | 13:13 EDT
Piper Jaffray analyst Edward Tenthoff said that the FDA's updated industry guidance on investigating and reporting adverse events related to human cellular and tissue-based products does not impose any new reporting requirements, since the agency already required the same reporting under guidance issued in 2005. Tenthoff, who believes the selloff in Osiris on the FDA news is overblown, keeps an Overweight rating and $18.50 price target on the stock.
News For OSIR From the Last 2 Days
There are no results for your query OSIR
